Minutes of Shanghai closed door meeting: the next five key points of drug bidding

Source: Cyprian 2015-6-18 yesterday, a warm-hearted micro friend shared the minutes of the closed door meeting of the 11th China Health Industry Summit Forum in 2015 Many of the dry goods in the minutes are worth pondering The following are the main contents of Zhu Hongbiao, deputy director of the Department of drug administration of the state health and Family Planning Commission: 1 In the first half of this year, the state has issued a series of policies, including the guiding opinions on the centralized purchase of drugs in public hospitals (No 7 document), etc in the second half of this year, a series of documents will be issued, and a series of documents on the reform of the drug field are under study and formulation This year, there will be a series of documents in the field of drug registration, evaluation and circulation 2 The national drug price negotiation document is in the process of countersigning and will be released soon Among them, what are the most concerned varieties that enter into the drug negotiation catalogue? After the drug price negotiation is started, the health and Family Planning Commission intends to negotiate with the national procurement volume The reference is the surrounding price Are the drug companies ready to reduce the price? How much is suitable? 3 The health and Family Planning Commission will issue document No 7 to implement the document, which requires all provinces to open bids in the middle and late November In the document, there are also clear provisions on the number of bid winning enterprises: in each group, the number of bid winning enterprises shall not exceed two at most 4 The problem of the original research drug: different from the original research drug, the original research drug is the expired patent drug, which is the same as other generic drugs in theory However, due to the differences in the quality of generic drugs at present, it is not possible to give a clear and unified answer to how to divide the bidding groups into several groups In the goal, we need to reduce the level of bidding group as much as possible and improve the degree of competition 5 The reasonable price rather than the lowest price for drug procurement This is a good turn for pharmaceutical enterprises Will it be implemented in the implementation document No 7 of the health and Family Planning Commission, and can it be implemented in details? Hope is no longer just a statement.